Clinical trial · Interventional
The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer
To Determine if MultiSpectral 3 Tesla MRI Can Provide Added Value in the Detection of Significant Cancers in Patients o n Active Surveillance for Prostate Cancer
NCT01896713CI-TRIAL-00011328completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
MultiSpectral 3 Tesla MRI (MS3TMRI) can increase the yield of Trans Rectal Ultrasound Biopsy (TRUSBx) to improve identification of patients on active surveillance requiring treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MS3TMRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Diagnostic: Single Arm
- description
- Imaging (MS3TMRI)
- interventionNames
- Other: MS3TMRI
Primary outcomes (1)
- measure
- The Positive Predictive Value (PPV) of MS3TMRI-TRUSBx for detection of a patient with a cancer burden requiring consideration of immediate therapy.
- timeFrame
- The outcome measure will be evaluated at the time of the results of the TRUSbx which will be approximately 2 weeks after the biopsy
- description
- Compare the targeted biopsy to the random biopsies
Secondary outcomes (1)
- measure
- The number of cores required for diagnosis of prostate cancer for MS3TMRI-TRUSBx versus TRUSBx alone
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Enrolled in active surveillance at Sunnybrook Health Sciences Centre, requiring biopsy as part of surveillance protocol. * Clinically eligible for radical prostatectomy and willing to undergo surgery * Clinically eligible for and willing to undergo ultrasound biopsy within 8 weeks of MRI Exclusion Criteria: * Claustrophobia * Contraindication to MRI * Contraindication to receiving low molecular weight MRI contrast agent * Prior hormone therapy except 5-alpha reductase inhibitors such as Avodart. FloMax etc * Clinically suspected or known compromised renal function or calculated estimated Glomerular Filtration Rate (eGFR) \<30ml/min
References
Publications (0)
Data not yet available
No reference posted for this study.